Analysis on the risk factors for organ damage in patients with systemic lupus erythematosus
a cross-sectional single-center experience
Palavras-chave:
Lupus erythematosus, systemic, Risk factors, Quality of lifeResumo
BACKGROUND: Organ damage in patients with systemic lupus erythematosus (SLE) occurs as a conse-quence of the disease itself, the therapy applied and the accompanying conditions and complications. Organ damage predicts further organ damage and is associated with an increased risk of death. OBJECTIVE: This study aimed to assess the degree of irreversible organ changes in SLE patients, using the Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) damage index (SDI); to establish correlations between organ damage and disease activity, quality of life, intensity of fatigue and serological factors; and to ascertain the risk factors for organ damage. DESIGN AND SETTING: Cross-sectional single-center study conducted at the Institute for Treatment and Rehabilitation “Niška Banja”, Niš, Serbia. METHODS: 83 patients with SLE were enrolled: 58 patients formed the group with organ damage (SDI ≥ 1), and 25 patients without organ damage served as controls (SDI = 0). RESULTS: Organ damage correlated with age (P = 0.002), disease duration (P = 0.015), disease activity (grade 1, P = 0.014; and grade 2, P = 0.007), poor quality of life, severe fatigue (P = 0.047) and treatment with azathi-oprine (P = 0.037). The following factors were protective: use of hydroxychloroquine (P = 0.048) and higher scores obtained for the physical (P = 0.011), mental (P = 0.022) and general health (P = 0.008) domains. CONCLUSION: It is very important to evaluate risk factors for organ damage in the body, including physi-cians’ overall assessment, to try to positively influence better treatment outcomes.
Downloads
Referências
Petri M, Purvey S, Fang H, Magder LS. Predictors of organ damage in systemic lupus erythematosus: the Hopkins Lupus Cohort. Arthritis Rheum. 2012;64(12):4021-8. PMID: 22932985; doi: 10.1002/art.34672.
Chambers SA, Allen E, Rahman A, Isenberg D. Damage and mortality in a group of British patients with systemic lupus erythematosus followed up for over 10 years. Rheumatology (Oxford). 2009;48(6):673-5. PMID: 19359343; doi: 10.1093/rheumatology/kep062.
Bruce IN, O’Keeffe AG, Farewell V, et al. Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort. Ann Rheum Dis. 2015;74(9):1706-13. PMID: 24834926; doi: 10.1136/annrheumdis-2013-205171.
Gladman D, Ginzler E, Goldsmith C, et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/ American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum. 1996;39(3):363-9. PMID: 8607884.
Strand V, Gladman D, Isenberg D, et al. Outcome measures to be used in clinical trials in systemic lupus erythematosus. J Rheumatol. 1999;26(2):490-7. PMID: 9972993.
Nuttall A, Isenberg DA. Assessment of disease activity, damage and quality of life in systemic lupus erythematosus: new aspects. Best Pract Res Clin Rheumatol. 2013;27(3):309-18. PMID: 24238688; doi: 10.1016/j. berh.2013.10.003.
Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40(9):1725. PMID: 9324032; doi: 10.1002/1529-0131(199709)40:9<1725::AID-ART29>3.0.CO;2-Y.
Petri M, Hellmann D, Hochberg M. Validity and reliability of lupus activity measures in the routine clinic setting. J Rheumatol. 1992;19(1):53-9. PMID: 1556700.
Ad Hoc Committee on Systemic Lupus Erythematosus Response Criteria for Fatigue. Measurement of fatigue in systemic lupus erythematosus: a systematic review. Arthritis Rheum. 2007;57(8):1348-57. PMID: 18050225; doi: 10.1002/art.23113.
Barbado J, Martin D, Vega L, et al. MCP-1 in urine as biomarker of disease activity in Systemic Lupus Erythematosus. Cytokine. 2012;60(2):583-6. PMID: 22857869; doi: 10.1016/j.cyto.2012.07.009.
Moroni G, Quaglini S, Radice A, et al. The value of a panel of autoantibodies for predicting the activity of lupus nephritis at time of renal biopsy. J Immunol Res. 2015;2015:106904. PMID: 25815344; doi: 10.1155/2015/106904.
Mok CC, Ho LY, Leung HW, et al. Performance of anti-C1q, antinucleosome, and antidsDNA antibodies for detecting concurrent disease activity of systemic lupus erythematosus. Transl Res. 2010;156(6):320-5. PMID: 21078493; doi: 10.1016/j.trsl.2010.07.009.
Zivković V, Stanković A, Cvetković T, et al. AntidsDNA, antinucleosome and antiC1q antibodies as disease activity markers in patients with systemic lupus erythematosus. Srp Arh Celok Lek. 2014;142(7-8):431-6. PMID: 25233687.
Chen Z, Li MT, Xu D, et al. Organ damage in patients with incomplete lupus syndromes: from a Chinese academic center. Clin Rheumatol. 2015;34(8):1383-9. PMID: 25687983; doi: 10.1007/s10067-015-2884-3.
Sutton EJ, Davidson JE, Bruce IN. The Systemic Lupus International Collaborating Clinics (SLICC) damage index: A systematic literature review. Semin Arthritis Rheum. 2013;43(3):352-61. PMID: 23786872; doi: 10.1016/j.semarthrit.2013.05.003.
Gonçalves MJ, Sousa S, Inês LS, et al. Characterization of damage in Portuguese lupus patients: analysis of a national lupus registry. Lupus. 2015;24(3):256-62. PMID: 25318970; doi: 10.1177/0961203314555172.
Ballocca F, D’Ascenzo F, Moretti C, et al. Predictors of cardiovascular events in patients with systemic lupus erythematosus (SLE): a systematic review and meta-analysis. Eur J Prev Cardiol. 2015;22(11):1435-41. PMID: 25139772; doi: 10.1177/2047487314546826.
Urowitz MB, Gladman DD, Ibañez D, et al. Evolution of disease burden over five years in a multicenter inception systemic lupus erythematosus cohort. Arthritis Care Res (Hoboken). 2012;64(1):132-7. PMID: 21954226; doi: 10.1002/acr.20648.
Akhavan PS, Su J, Lou W, et al. The early protective effect of hydroxychloroquine on the risk of cumulative damage in patients with systemic lupus erythematosus. J Rheumatol. 2013;40(6):831-41. PMID: 23588942; doi: 10.3899/jrheum.120572.
Sterling K, Gallop K, Swinburn P, et al. Patient-reported fatigue and its impact on patients with systemic lupus erythematosus. Lupus. 2014;23(2):124-32. PMID: 24197552; doi: 10.1177/0961203313511554.
Yee CS, Hussein H, Skan J, et al. Association of damage with autoantibody profile, age, race, sex and disease duration in systemic lupus erythematosus. Rheumatology (Oxford). 2003;42(2):276-9. PMID: 12595622; doi: 10.1093/rheumatology/keg078.
Prasad R, Ibañez D, Gladman D, Urowitz M. Anti-dsDNA and anti-Sm antibodies do not predict damage in systemic lupus erythematosus. Lupus. 2006;15(5):285-91. PMID: 16761503; doi: 10.1191/0961203306lu2302oa.
Zahr ZA, Fang H, Magder LS, Petri M. Predictors of corticosteroid tapering in SLE patients: the Hopkins Lupus Cohort. Lupus. 2013;22(7):697-701. PMID: 23708944; doi: 10.1177/0961203313490434.
Nossent JC. SLICC/ACR Damage Index in Afro-Caribbean patients with systemic lupus erythematosus: changes in and relationship to disease activity, corticosteroid therapy, and prognosis. J Rheumatol. 1998;25(4):654-9. PMID: 9558165.
Parker B, Urovitz MB, Gladman DD, et al. Impact of early disease factors on metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort. Ann Rheum Dis. 2015;74(8):1530-6. PMID: 24692585; doi: 10.1136/annrheumdis-2013-203933.
Demir S, Artim-Esen B, Şahinkaya Y, et al. Metabolic syndrome is not only a risk factor for cardiovascular diseases in systemic lupus erythematosus but is also associated with cumulative organ damage: a cross-sectional analysis of 311 patients. Lupus. 2016;25(2):177-84. PMID: 26354963; doi: 10.1177/0961203315603140.
Ruiz-Irastorza G, Egurbide MV, Martinez-Berriotxoa A, et al. Antiphospholipid antibodies predict early damage in patients with systemic lupus erythematosus. Lupus. 2004;13(12):900-5. PMID: 15645743; doi: 10.1191/0961203304lu2030oa.
Mok CC, Ho LY, Cheung MY, Yu KL, To CH. Effect of disease activity and damage on quality of life in patients with systemic lupus erythematosus: a 2-year prospective study. Scand J Rheumatol. 2009;38(2):121-7. PMID: 18991189; doi: 10.1080/03009740802415527.
Schmeding A, Schneider M. Fatigue, health-related quality of life and other patient-reported outcomes in systemic lupus erythematosus. Best Pract Res Clin Rheumatol. 2013;27(3):363-75. PMID: 24238693; doi: 10.1016/j.berh.2013.07.009.
Becker-Merok A, Nossent HC. Damage accumulation in systemic lupus erythematosus and its relation to disease activity and mortality. J Rheumatol. 2006;33(8):1570-7. PMID: 16845708.
Watson P, Brennan A, Birch H, Fang H, Petri M. An integrated extrapolation of long-term outcomes in systemic lupus erythematosus: analysis and simulation of the Hopkins lupus cohort. Rheumatology (Oxford). 2015;54(4):623-32. PMID: 25234659; doi: 10.1093/rheumatology/keu375.
Taraborelli M, Cavazzana I, Martinazzi N, et al. Organ damage accrual and distribution in systemic lupus erythematosus patients followed-up for more than 10 years. Lupus. 2017; 26(11):1197-204. PMID: 28420047; doi: 10.1177/0961203317693096.
Downloads
Publicado
Como Citar
Edição
Seção
Licença
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
